You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!
NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
St. Helier, Jersey
52 Week High
52 Week Low
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019
NovoCure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2019, March 29 through April 3, in Atlanta.
Novocure’s Chief Science Officer retires
Novocure (NASDAQ:NVCR) Chief Science Officer and Head of R&D, Dr. Eilon Kirson will retire effective May 1, to spend more time with his family.
Novocure’s Chief Science Officer Retires after 17 Years of Service
NovoCure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family.
Expected Apr 25, Pre-Market